iShares Biotechnology ETF
954 hedge funds and large institutions have $7.61B invested in iShares Biotechnology ETF in 2026 Q2 according to their latest regulatory filings, with 118 funds opening new positions, 245 increasing their positions, 317 reducing their positions, and 72 closing their positions.
95% more call options, than puts
Call options by funds: $292M | Put options by funds: $150M
64% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 72
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
8% more capital invested
Capital invested by funds: $7.04B → $7.61B (+$572M)
4% more funds holding
Funds holding: 921 → 954 (+33)
2.27% less ownership
Funds ownership: 86.51% → 84.24% (-2.3%)
23% less repeat investments, than reductions
Existing positions increased: 245 | Existing positions reduced: 317
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$177M |
| 2 |
Morgan Stanley
New York
|
+$94.1M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$30.1M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$22.3M |
| 5 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$315M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$97M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$66.1M |
| 4 |
Citigroup
New York
|
-$62.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$55M |
IBB Hedge Fund Activity: Q2 2026 in Review
954 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2026, worth a combined $7.61B — up 8.1% from $7.04B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new IBB positions and 72 closed out — a net gain of 46 holders — while 245 added to existing stakes and 317 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $177M. The largest seller was JP Morgan Chase, cutting an estimated $315M.
- 954 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2026, up from 921 in Q1 2026.
- Funds reported $7.61B of iShares Biotechnology ETF stock for Q2 2026, up 8.1% quarter-over-quarter.
- 118 funds opened new iShares Biotechnology ETF positions in Q2 2026 and 72 closed out, a net change of +46 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2026 was Two Sigma Investments, an estimated $177M added.
- The largest iShares Biotechnology ETF seller in Q2 2026 was JP Morgan Chase, an estimated $315M sold.
Based on aggregated 13F filings for Q2 2026.